会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • Breast cancer resistance protein (BCRP) inhibitor
    • 乳腺癌抗性蛋白(BCRP)抑制剂
    • US07371773B2
    • 2008-05-13
    • US10544064
    • 2004-02-03
    • Ryuta YamazakiYukiko NishiyamaTomio FurutaTakeshi MatsuzakiHiroshi HatanoOh YoshidaMasato NagaokaRitsuo AiyamaShusuke HashimotoYoshikazu Sugimoto
    • Ryuta YamazakiYukiko NishiyamaTomio FurutaTakeshi MatsuzakiHiroshi HatanoOh YoshidaMasato NagaokaRitsuo AiyamaShusuke HashimotoYoshikazu Sugimoto
    • A61K31/415
    • C07D211/58A61K31/277A61K31/7034C07C255/37C07D317/60
    • The invention provides a drug which inhibits BCRP.A breast cancer resistance protein inhibitor containing, as an active ingredient, a diphenylacrylonitrile derivative represented by the following formula (1): [wherein, each of 8 R's, which are the same or different from one another, represents a hydrogen atom, a hydroxyl group, a nitro group, an amino group, an acetylamino group (—NHCOCH3 group); a cyano group (—CN group); a formyl group (—CHO group), —COOR1 (R1 is hydrogen or C1-C4 alkyl), —O(CH2)nCOOR2 (n=1−7: R2 is hydrogen or C1-C4 alkyl), —OOCCH2CH2COOR3 (R3 is hydrogen, C1-C4 alkyl, (Z)-2-(3,4-dimethoxy-phenyl)-3-(4-hydroxy-phenyl)-acrylonitrile, or glycopyranosyl), a C1-C8 alkoxy group, a C1-C4 alkyl group, a halogen atom, a C1-C4 alkoxy C1-C4 alkoxy C1-C4 alkoxy group, a C2-C8 acyloxy group, a C2-C8 halogenoacyloxy group, a methylenedioxy group, a trifluoromethyl group, a phosphate group (i.e., —OP(O) (OH)2) or a salt thereof, a sulfate group (i.e., —OSO3H) or a salt thereof, a glycopyranosyl group or a salt thereof, a phosphate ester of a glycopyranosyl group or a salt of the ester, a sulfate ester of a glycopyranosyl group or a salt of the ester, or a piperidinopiperidinocarbonyloxy group], an ester thereof, or a salt thereof.
    • 本发明提供抑制BCRP的药物。 作为活性成分,含有下述式(1)表示的二苯基丙烯腈衍生物的乳
      球癌抗性蛋白质抑制剂:[其中,8个相同或不同的8个R代表氢原子,羟基 基团,硝基,氨基,乙酰氨基(-NHCOCH 3 SO 3); 氰基(-CN基); 甲酰基(-CHO基),-COOR 1(R 1是氢或C 1 -C 4烷基),-O(CH 2) )nOR 2(n = 1-7:R 2是氢或C 1 -C 4烷基),-OOCCH 2 (R 3)是氢,C 1 -C 4烷基,(Z)-2-(3,4-二氯苯基) 二甲氧基 - 苯基)-3-(4-羟基 - 苯基) - 丙烯腈或糖吡喃糖基),C1-C8烷氧基,C1-C4烷基,卤素原子,C1-C4烷氧基C1-C4烷氧基C1- C4烷氧基,C2-C8酰氧基,C2-C8卤代酰氧基,亚甲二氧基,三氟甲基,磷酸基(即-OP(O)(OH)2))或 其盐,硫酸基(即-OSO 3 H)或其盐,糖吡喃糖基或其盐,糖吡喃糖基的磷酸酯或酯的盐, 糖吡喃糖基的硫酸酯或酯的盐或哌啶子基哌啶羰基氧基],其酯或其盐。
    • 7. 发明申请
    • Breast cancer resistance protein (bcrp) inhibitor
    • 乳腺癌抗性蛋白(bcrp)抑制剂
    • US20060128636A1
    • 2006-06-15
    • US10544064
    • 2004-02-03
    • Ryuta YamazakiYukiko NishiyamaTomio FurutaTakeshi MatsuzakiHiroshi HatanoOh YoshidaMasato NagaokaRitsuo AiyamaShusuke HashimotoYoshikazu Sugimoto
    • Ryuta YamazakiYukiko NishiyamaTomio FurutaTakeshi MatsuzakiHiroshi HatanoOh YoshidaMasato NagaokaRitsuo AiyamaShusuke HashimotoYoshikazu Sugimoto
    • A61K31/7034A61K31/277A61K31/66
    • C07D211/58A61K31/277A61K31/7034C07C255/37C07D317/60
    • The invention provides a drug which inhibits BCRP. A breast cancer resistance protein inhibitor containing, as an active ingredient, a diphenylacrylonitrile derivative represented by the following formula (1): [wherein, each of 8 R's, which are the same or different from one another, represents a hydrogen atom, a hydroxyl group, a nitro group, an amino group, an acetylamino group (—NHCOCH3 group); a cyano group (—CN group); a formyl group (—CHO group), —COOR1 (R1 is hydrogen or C1-C4 alkyl), —O(CH2)nCOOR2 (n=1−7: R2 is hydrogen or C1-C4 alkyl), —OOCCH2CH2COOR3 (R3 is hydrogen, C1-C4 alkyl, (Z)-2-(3,4-dimethoxy-phenyl)-3-(4-hydroxy-phenyl)-acrylonitrile, or glycopyranosyl), a C1-C8 alkoxy group, a C1-C4 alkyl group, a halogen atom, a C1-C4 alkoxy C1-C4 alkoxy C1-C4 alkoxy group, a C2-C8 acyloxy group, a C2-C8 halogenoacyloxy group, a methylenedioxy group, a trifluoromethyl group, a phosphate group (i.e., —OP(O) (OH)2) or a salt thereof, a sulfate group (i.e., —OSO3H) or a salt thereof, a glycopyranosyl group or a salt thereof, a phosphate ester of a glycopyranosyl group or a salt of the ester, a sulfate ester of a glycopyranosyl group or a salt of the ester, or a piperidinopiperidinocarbonyloxy group], an ester thereof, or a salt thereof.
    • 本发明提供抑制BCRP的药物。 作为活性成分,含有下述式(1)表示的二苯基丙烯腈衍生物的乳
      球癌抗性蛋白质抑制剂:[其中,8个相同或不同的8个R代表氢原子,羟基 基团,硝基,氨基,乙酰氨基(-NHCOCH 3 SO 3); 氰基(-CN基); 甲酰基(-CHO基),-COOR 1(R 1是氢或C 1 -C 4烷基),-O(CH 2) )nOR 2(n = 1-7:R 2是氢或C 1 -C 4烷基),-OOCCH 2 (R 3)是氢,C 1 -C 4烷基,(Z)-2-(3,4-二氯苯基) 二甲氧基 - 苯基)-3-(4-羟基 - 苯基) - 丙烯腈或糖吡喃糖基),C1-C8烷氧基,C1-C4烷基,卤素原子,C1-C4烷氧基C1-C4烷氧基C1- C4烷氧基,C2-C8酰氧基,C2-C8卤代酰氧基,亚甲二氧基,三氟甲基,磷酸基(即-OP(O)(OH)2))或 其盐,硫酸基(即-OSO 3 H)或其盐,糖吡喃糖基或其盐,糖吡喃糖基的磷酸酯或酯的盐, 糖吡喃糖基的硫酸酯或酯的盐或哌啶子基哌啶羰基氧基],其酯或其盐。
    • 9. 发明授权
    • Memory controller and memory controlling method
    • 内存控制器和内存控制方式
    • US08422330B2
    • 2013-04-16
    • US13242990
    • 2011-09-23
    • Hiroshi HatanoTakashi NishikawaMasahiko Toichi
    • Hiroshi HatanoTakashi NishikawaMasahiko Toichi
    • G11C8/08
    • G06F9/3455G06F9/30043G06F9/30109G06F9/345
    • A memory controller includes: a first generating unit that generates a read-address to read a data element sequence having a plurality of data elements from a bank of a memory; a second generating unit that generates a position signal indicating a position of a data element to be selected from the data element sequence, and an order signal indicating a storing order for storing the data element to be selected into a register; and a selector unit that selects, according to the position signal, the data element to be selected from the data element sequence read out from each of the plurality of the banks, and stores the selected data element in the storing order indicated by the order signal into the register, wherein the data element stored in the register is processed in the storing order by a vector processor.
    • 存储器控制器包括:第一生成单元,其生成读取地址以从存储器的存储体读取具有多个数据元素的数据元素序列; 第二生成单元,生成指示要从数据元素序列中选择的数据元素的位置的位置信号,以及指示用于将要选择的数据元素存储到寄存器中的存储顺序的顺序信号; 以及选择器单元,其根据所述位置信号从从所述多个存储体中的每一个读出的数据元素序列中选择要选择的数据元素,并将所选择的数据元素存储在由所述订单信号指示的存储顺序中 进入寄存器,其中通过矢量处理器以存储顺序处理存储在寄存器中的数据元素。